Pan Arab Journal of Oncology - Arab Medical Association Against ...

objectives & scope of the PAJO <
The Pan Arab Journal of Oncology (PAJO) is the official Journal of the Arab Medical Association Against Cancer (AMAAC). It is a
quarterly publication targeting health professionals interested in the oncology field. It is a multidisciplinary peer-reviewed journal that
publishes articles addressing medical oncology, malignant hematology, surgery, radiotherapy, pediatric oncology, geriatric oncology,
basic research and the comprehensive management of patients with malignant diseases in addition to international oncology activities,
congresses & news.
The journal will be addressed, as a first step, mainly to the professionals in the hematology & oncology field in the Middle East
region and North Africa. The goal is to share local & regional research activities news and to be updated with international activities.
We hope, with your support, to achieve our following objectives:
1. Promote and encourage research activities in the Arab World.
2. Disseminate & analyze epidemiological local, regional and international data.
3. Update health professionals with the most recent advances, news & developments in the field of oncology.
4. Improve the level of scientific publications arising form the Arab World.
5. Keep health professionals connected and exposed to the activities of different Arab cancer societies.
6. Share with our immigrant compatriots their activities & feedback in this field.
7. Involve all health professionals interested in the field of Oncology within the multidisciplinary scope of the Journal.
8. Encourage post graduates students to submit their research work.
instructions for authors <
1. Manuscript Categories
1.1. Clinical trials
The Editor-in-Chief and an Associate Editor generally review
Reports from clinical trials. Selected manuscripts are also reviewed
by at least two external peer reviewers. Comments offered by
reviewers are returned to the author(s) for consideration.
Manuscript acceptance is based on many factors, including the
importance of the research to the field of oncology & the quality
of the study. Authors should focus on accuracy, clarity, and brevity
in their presentation, and should avoid lengthy introductions,
repetition of data from tables and figures in the text, and unfocused
discussions. Extended patient demographic data should be included
in a table, not listed within the text.
Reports from Clinical trials are limited to 3,000 words of body
text, excluding the abstract, references, figures, and tables. They
are limited to six total figures and tables. All abstracts are strictly
limited to 250 words. Titles are to be descriptive, but succinct.
Results of clinical studies should be supported by a clear
description of the study design, conduct, and analysis methods
used to obtain the results.
Reports of phase II & III studies should include from the protocol
a clear definition of the primary end point, the hypothesized value
of the primary end point that justified the planned sample size,
and a discussion of possible weaknesses, such as comparison to
historical controls.
Phase I studies will be well received if they have interesting clinical
responses, unusual toxicity that pointed to mechanism of action of
the agents, and important or novel correlative laboratory studies
associated with the trials.
1.2. Review Articles
All reviews must be clinically oriented, ie, at least half the review
must describe studies that detail human impact, marker effect on
prognosis, or clinical trials.
Review Articles should be prepared in accordance with the Journal’s
Manuscript Preparation Guidelines, and will be reviewed in the
same manner as Reports from Clinical Trials. Reviews are limited
to 4,500 words of body text, excluding the abstract, references,
figures, and tables. The editors also suggest a limit of 150 references.
1.3. Editorials / Comments / Controversies
The Editor-in-Chief may solicit an Editorial to accompany an
accepted manuscript. Authors who wish to submit unsolicited
Comments and Controversies should contact the Editor-in-Chief,
before submission to determine the appropriateness of the topic
for publication in the Journal.
Editorials should be no more than four to five pages in length.
1.4. Articles on Health Economics
Articles about health economics (cost of disease, cost-effectiveness
of drugs, etc) are highly encouraged.
1.5. Case Reports / Correspondence / Special Articles
Correspondence (letters to the Editor) may be in response to a
published article, or a short, free-standing piece expressing an
opinion, describing a unique case, or reporting an observation that
would not qualify as an Original Report. If the Correspondence is
in response to a published article, the Editor-in-Chief may choose
to invite the article’s authors to write a Correspondence reply.
Correspondence should be no longer than three pages in length.
Special Articles present reports, news from international, regional
societies as well as news from our compatriots.
www.amaac.org Pan Arab Journal of Oncology | vol 5; issue 3 | September 2012 < 45